Our Priorities Access to Medical Technology

Health Technology Assessment

assistance female doctor point and show Advanced medical equipment vital sign monitor display in hospital operation surgery room ward health concept

Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system. *

HTA systematically evaluates the relative effectiveness, cost-effectiveness and economic, social and organisational impact of health technologies on the lives of patients, healthcare systems and society. The relative effects of a technology or solution are compared to current practices.

HTA reports aim to inform decision-making on, for example, appropriate use, clinical guidelines or national/regional funding.

MedTech Europe welcomes advances in the assessment of medical technology innovations, and the appropriate rewarding of the value these innovations bring. The assessment of the value of medical technologies should take place using tools that are appropriate to the nature of the sector and its innovation model.

In specific cases, HTA can be used to assess a medical technology, for specific purposes and at specific times and implemented to address the specific country needs. This reflects the decentralised and localised market access model, well-suited for Member States’ decision-making.

*HTAi reference

MedTech Europe’s view on HTA

Fundamental guiding principles of HTA for medical technology and solutions in Europe today shall be: clear purpose of HTA, transparency of the process, appropriate timing and adaptive evidence profile.

At a European level, since years, cooperation in the field of HTA has been ongoing through European joint actions, and the HTA Network within the cross-border Directive to which MedTech Europe has actively participated. As of end of 2021, the Directive had been replaced by a Regulation introducing newly defined cooperation in the field of HTA (HTAR).

Our team supports the creation of an appropriate policy environment and initiatives that:

Promote timely access to, and funding of, innovation.
Enable accelerated and equal accessibility of innovative technologies.
Enhance the use of innovative technologies in healthcare delivery healthcare, to contribute to more sustainable and resilient national health systems.

The road ahead

MedTech Europe will maintain an active role throughout the Regulation’s implementation phase (foreseen until 2025) and beyond. As a member of the Stakeholder Network, maintaining a strong voice will involve: interactions with the Coordination Group’s medical technology configuration and respective subgroups, as well as engaging in a dialogue with the EU Institutions and strengthening our relationship with relevant stakeholders.

MedTech Europe will uphold a strong participation in terms of EUnetHTA21 public consultations. Thus, we will continue to respond to EUnetHTA21 consultations in an attempt to foster an environment where, new methodologies and jointly build out proposals will arise.

At this time, particular focus will be given to the new EU Regulation on HTA. Key focus areas will include the newly defined cooperations such as: Joint Clinical Assessments, Joint Scientific Consultations and Identification of Emerging Innovations, where many open questions remain, and further work is needed if HTA cooperation in Europe is to truly deliver better-informed investment decisions and accelerated patient access to innovation. Hereby recognizing the specificities of medical technologies (medical devices, In-vitro diagnostics, digital and other technologies).

In our view, key factors of success are: securing high-quality expertise in the field of medical technology, building out dedicated methodologies and the involvement of Health Technology Developers (HTD) in the processes.

At all times, any assessment on health technologies, that is to have true value, will need to have a clear purpose and inform decisions of adoption and investment/funding. Equally important is to have no interference with other legislations, avoiding the risk of ambiguity and duplication.

MedTech Europe’s overarching aim is to make the latest medical technology innovations available to European citizens while mitigating the risk of: delays in access to technologies for patients and healthcare systems; an increased burden for the medical technology industry and deprioritising Europe, as a preferred market to innovate.

Yves Verboven

Senior Adviser - External Consultant
eS52ZXJib3ZlbkBtZWR0ZWNoZXVyb3BlLm9yZw==

Yves Verboven

Senior Adviser - External Consultant

Medtech Europe

eS52ZXJib3ZlbkBtZWR0ZWNoZXVyb3BlLm9yZw==

Yves leads the Access & Economic Policies team, which focuses on European legislative and research initiatives in fields such as procurement, health technology assessment, evidence generation representing the medical technology industry view and deploying own initiatives striving to have a timely access for medical technologies and solutions and have these appropriately used and rewarded.

Yves has an applied science and engineering background with further education in Business administration and health economics. Yves considers the area of medical technologies, which transfers the engineering world into something as good and valuable as health, a prerequisite for well-being and happiness, a great motivator.

Together with the team, his focus is not only on the health issue challenges but also to the health system challenges, to offer best care and to do this without waste, inefficiency, complication and see this incorporated into the policies when assessing medical technology. This supports a change to a value-based model of access and awarding of new medical technology value propositions.

In the medical technology industry, Yves has expertise in the field of clinical engineering, first in human studies, clinical and health economic outcomes trials and analysis, reimbursement, and then, after moving to MedTech Europe, with a focus on policies and advancing the medical technology access model striving to a value-based access model, and having the appropriate instruments in place to award and reward the value of medical technology.

In his free time, Yves loves to fly over the waves and lakes steering a catamaran.

See full team

Key topics

Male nurse pushing stretcher gurney bed in hospital corridor with doctors and senior female patient

Value-based Procurement

Public procurement refers to the formal process (tender) by which public authorities, such as government departments, local authorities or public hospitals, purchase work, goods or services from external companies.

Ultrasonic monitoring of patient's heart during cardiac surgery

Financing of Medical Technology

In Europe, most medical technologies are paid for by public health authorities, usually within a third-party payer system.

Value of Diagnostic Information (VODI)

In vitro diagnostics (IVDs) are non-invasive tests used on samples from the human body (e.g., blood, urine, or tissues) to determine the status of a person’s health. Their value resides in the quality of information they provide, which is timely, precise, and patient-specific.